Fast, accurate treatment decisions for NSCLC patients
ASPYRE’s comprehensive lung panel simultaneously analyzes DNA and RNA from blood or tissue in a single assay, enabling straightforward, precise identification of all NCCN guideline recommended genomic biomarkers associated with approved targeted therapies for NSCLC.
Fast time to treatment
ASPYRE-Lung dramatically simplifies and accelerates the detection of actionable biomarkers, enabling you to identify targeted treatment options within days of diagnosis.
Reduced sample requirement
ASPYRE’s high sensitivity enables testing from tissue samples with as little as 10% tumor content, compared to 20% or 30% for most competing assays.
ASPYRE accelerates and simplifies analysis by eliminating the noise from genomic data, ensuring accuracy for the markers that are of interest, to enable more confident decision-making.
ASPYRE’s high sensitivity enables accurate biomarker analysis from blood or tissue, even from limited samples with low tumor content.
Biomarkers included in ASPYRE-Lung
ASPYRE-Lung enables the simultaneous analysis of 77 DNA mutations & 37 RNA fusions.